---
input_text: "The role of colchicine in the management of COVID-19: a Meta-analysis.
  BACKGROUND: The Coronavirus disease 2019 (COVID-19) pandemic has robustly affected
  the global healthcare and economic systems and it was caused by coronavirus-2 (SARS-CoV-2).
  The clinical presentation of the disease ranges from a flu-like illness to severe
  pneumonia and death. Till September 2022, the cumulative number of cases exceeded
  600 million worldwide and deaths were more than 6 million. Colchicine is an alkaloid
  drug that is used in many autoinflammatory conditions e.g., gout, familial Mediterranean
  fever, and Behcet's syndrome. Colchicine inhibits the production of superoxide and
  the release of interleukins that stimulate the inflammatory cascade. Colchicine
  decreases the differentiation of myofibroblast and the release of fibrotic mediators
  including transforming growth factor (TGF-beta1) that are related to the fibrosis.
  Moreover, colchicine has been used to traet viral myocarditis caused by CMV or EBV,
  interstitial pneumonia, and pericarditis resulting from influenza B infection. Additionally,
  colchicine is considered safe and affordable with wide availability. OBJECTIVE:
  The aim of the current study was to assess the evidence of colchicine effectiveness
  in COVID-19 treatment. METHODS: A comprehensive review of the literature was done
  till May 2022 and yielded 814 articles after ranking the articles according to authors
  and year of publication. Only 8 clinical trials and cohort studies fulfilling the
  inclusion criteria were included for further steps of data collection, analysis,
  and reporting. RESULTS: This meta-analysis involved 16,488 patients; 8146 patients
  in the treatment group and 8342 patients in the control group. The results showed
  that colchicine resulted in a significant reduction in the mortality rate among
  patients received colchicine in comparison with placebo or standard care (RR 0.35,
  95%CI: 0.15-0.79). Colchicine resulted in a significant decrease in the need for
  O2 therapy in patients with COVID-19 (RR 0.07, 95%CI 0.02-0.27, P = 0.000024). However,
  colchicine had no significant effect on the following outcomes among COVID-19 patients:
  the need for hospitalization, ICU admission, artificial ventilation, and hospital
  discharge rate. Among the PCR confirmed COVID-19 patients, colchicine decreased
  the hospitalization rate (RR 0.75, 95%CI 0.57-0.99, P = 0.042). However, colchicine
  had no effect on mortality and the need for mechanical ventilation among this subgroup.
  CONCLUSION: Colchicine caused a significant clinical improvement among COVID-19
  patients as compared with the standard care or placebo, in terms of the need for
  O2, and mortality. This beneficial effect could play a role in the management of
  COVID-19 especially severe cases to decrease need for oxygen and to decrease mortality
  among these patients."
raw_completion_output: |-
  primary_disease: COVID-19
  medical_actions: Use of colchicine;Reduction in mortality rate with colchicine;Decrease in the need for O2 therapy with colchicine;Review of literature;Data collection, analysis, and reporting;Meta-analysis
  symptoms: flu-like illness;severe pneumonia;death
  chemicals: colchicine
  action_annotation_relationships: Use of colchicine TREATS flu-like illness IN COVID-19;Use of colchicine TREATS severe pneumonia IN COVID-19;Use of colchicine (with colchicine) TREATS death IN COVID-19;Reduction in mortality rate with colchicine TREATS death IN COVID-19;Decrease in the need for O2 therapy with colchicine TREATS severe pneumonia IN COVID-19
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Decrease in the need for O2 therapy with colchicine TREATS severe pneumonia IN COVID-19

  ===

extracted_object:
  primary_disease: MONDO:0100096
  medical_actions:
    - Use of colchicine
    - Reduction in mortality rate with colchicine
    - Decrease in the need for O2 therapy with colchicine
    - Review of literature
    - Data collection, analysis, and reporting
    - Meta-analysis
  symptoms:
    - flu-like illness
    - severe pneumonia
    - death
  chemicals:
    - CHEBI:23359
  action_annotation_relationships:
    - subject: Use of colchicine
      predicate: TREATS
      object: flu-like illness
      qualifier: MONDO:0100096
      subject_extension: CHEBI:23359
    - subject: Use of colchicine
      predicate: TREATS
      object: severe pneumonia
      qualifier: MONDO:0100096
      object_qualifier: severe
      subject_extension: CHEBI:23359
    - subject: Use of colchicine
      predicate: TREATS
      object: death
      qualifier: MONDO:0100096
      subject_qualifier: with colchicine
      subject_extension: CHEBI:23359
    - subject: Reduction in mortality rate
      predicate: TREATS
      object: death
      qualifier: MONDO:0100096
      subject_extension: CHEBI:23359
    - subject: O2 therapy
      predicate: TREATS
      object: severe pneumonia
      qualifier: MONDO:0100096
      subject_qualifier: Decrease in the need for
      subject_extension: CHEBI:23359
named_entities:
  - id: MONDO:0018456
    label: Polyarticular Juvenile Idiopathic Arthritis
  - id: CHEBI:44185
    label: Methotrexate
  - id: MONDO:0005554
    label: Rheumatic diseases
  - id: HP:0000988
    label: Rash
  - id: HP:0000989
    label: Itching
  - id: HP:0002315
    label: Headache
  - id: HP:0002027
    label: Abdominal pain
  - id: CHEBI:4875
    label: Etanercept
  - id: CHEBI:231683
    label: Anakinra
  - id: CHEBI:64360
    label: Tocilizumab
  - id: CHEBI:64357
    label: Rituximab
  - id: CHEBI:29007
    label: Ceftriaxone
  - id: CHEBI:8776
    label: Ranitidine
  - id: MONDO:0019167
    label: IgA vasculitis (IgAV)
  - id: HP:0002829
    label: arthralgia
  - id: HP:0001369
    label: arthritis
  - id: HP:0000790
    label: hematuria
  - id: HP:0033404
    label: intestinal ischemia
  - id: CHEBI:28304
    label: enoxaparin
  - id: CHEBI:6888
    label: methylprednisolone
  - id: CHEBI:63916
    label: iloprost
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: MONDO:0018088
    label: AA amyloidosis secondary to familial Mediterranean fever (FMF)
  - id: HP:4000041
    label: AA amyloidosis
  - id: MONDO:0019439
    label: AA amyloidosis
  - id: MONDO:0025484
    label: Systemic Autoinflammatory Diseases (SAIDs)
  - id: HP:0001954
    label: Recurrent fever
  - id: HP:0000093
    label: Proteinuria
  - id: CHEBI:23359
    label: Colchicine
  - id: HP:0045073
    label: Serositis
  - id: HP:0000711
    label: Restlessness
  - id: MONDO:0005052
    label: Inflammatory Bowel Disease (IBD)
  - id: MAXO:0000748
    label: Fecal microbiota transplantation
  - id: MONDO:0005191
    label: Metastatic Melanoma
  - id: HP:0011034
    label: Amyloidosis
  - id: HP:0004325
    label: Decreased body weight
  - id: CHEBI:46345
    label: 5-Fluorouracil
  - id: MONDO:0019324
    label: Periodic Fever Syndromes (PFS)
  - id: CHEBI:35475
    label: NSAIDs
  - id: HP:0012824
    label: Severity
  - id: HP:0040279
    label: frequency
  - id: MONDO:0100096
    label: COVID-19
  - id: MAXO:0010317
    label: chest CT
  - id: HP:0001907
    label: thromboembolism
  - id: HP:0033677
    label: acute respiratory distress syndrome
  - id: CHEBI:25805
    label: oxygen
  - id: CHEBI:33281
    label: antibiotics
  - id: CHEBI:231491
    label: CRP
  - id: HP:0000010
    label: Urinary tract infections
  - id: HP:0002090
    label: pneumonia
  - id: HP:0032169
    label: severe infections
  - id: MONDO:0008876
    label: Behcet's syndrome (BS) and familial Mediterranean fever (FMF)
  - id: HP:0000554
    label: Uveitis
  - id: HP:0001297
    label: Stroke
  - id: HP:0001945
    label: Fever
  - id: HP:0005059
    label: Arthralgia/arthritis
  - id: MAXO:0001017
    label: Vaccination
  - id: MONDO:0007191
    label: Behcet's syndrome
  - id: HP:0031844
    label: Euphoria
  - id: HP:0000738
    label: Hallucinations
  - id: HP:0002013
    label: Vomiting
  - id: HP:0002321
    label: Dizziness
  - id: HP:0000739
    label: Anxiety
  - id: HP:0003552
    label: Muscle stiffness
  - id: CHEBI:4604
    label: Dimenhydrinate
  - id: CHEBI:3048
    label: Benztropine
  - id: CHEBI:6539
    label: Lorazepam
  - id: MAXO:0010032
    label: heart transplantation
  - id: CHEBI:4031
    label: cyclosporine
  - id: CHEBI:8764
    label: mycophenolate mofetil
  - id: CHEBI:8378
    label: prednisolone
  - id: HP:0100665
    label: Angioedema
  - id: HP:0012378
    label: Fatigue
  - id: MAXO:0000602
    label: hemodialysis
  - id: MAXO:0000127
    label: genetic testing
  - id: HP:0032323
    label: periodic fever
  - id: CHEBI:75045
    label: Dabrafenib
  - id: CHEBI:75998
    label: Trametinib
  - id: MONDO:0019434
    label: Systemic Juvenile Idiopathic Arthritis (sJIA)
  - id: MAXO:0000336
    label: Bone marrow biopsy
  - id: HP:0003326
    label: Myalgia
  - id: HP:0003565
    label: Increased erythrocyte sedimentation rate
  - id: HP:0002155
    label: Increased triglycerides
  - id: CHEBI:50858
    label: Corticosteroids
  - id: HP:0012622
    label: chronic kidney disease
  - id: MAXO:0001298
    label: therapy
  - id: MONDO:0017708
    label: mevalonate kinase deficiency
  - id: MONDO:0007727
    label: TRAPS
  - id: MONDO:0009279
    label: AA amyloidosis (AAA)
  - id: HP:0001511
    label: intrauterine growth retardation
  - id: HP:0100602
    label: preeclampsia
  - id: MONDO:0004995
    label: Cardiovascular Disease
  - id: CHEBI:15365
    label: Aspirin
  - id: HP:0001626
    label: Cardiovascular Disease
  - id: HP:0001919
    label: acute kidney injury
  - id: HP:0032437
    label: reduced C-reactive protein levels
  - id: MONDO:0005300
    label: chronic kidney disease
  - id: HP:0002014
    label: Loose stools
  - id: HP:0000822
    label: Hypertension
  - id: HP:0011947
    label: Respiratory tract infections
  - id: HP:0031972
    label: Presyncope
  - id: HP:0002094
    label: Dyspnea
  - id: HP:0002039
    label: Anorexia
  - id: HP:0002018
    label: Nausea
  - id: HP:0002910
    label: Elevated liver enzymes
  - id: CHEBI:9513
    label: Thalidomide
  - id: HP:0000622
    label: Blurred vision
  - id: HP:0008043
    label: Retinal arteriolar narrowing
  - id: HP:0025240
    label: Preretinal hemorrhages
  - id: HP:0002415
    label: Leukodystrophy (as observed in MRI)
  - id: CHEBI:63895
    label: interleukin (IL)-1 inhibitor
  - id: CHEBI:5801
    label: hydroxychloroquine
  - id: MAXO:0000015
    label: biologic therapy
  - id: CHEBI:63580
    label: ribavirin
  - id: HP:0012213
    label: decreased Glomerular Filtration Rate (GFR)
  - id: MONDO:0012268
    label: Adult-onset systemic autoinflammatory disorders (AIDs)
  - id: CHEBI:35705
    label: Immunosuppressive agents
  - id: CHEBI:35341
    label: Steroids
  - id: HP:0001677
    label: Coronary artery disease
  - id: HP:0002621
    label: Atherosclerosis
  - id: HP:0001635
    label: Heart failure
  - id: HP:0001658
    label: Myocardial infarction
  - id: MONDO:0005393
    label: Gout
  - id: CHEBI:143125
    label: Monosodium urate crystals
  - id: MONDO:0005240
    label: renal disease
  - id: MAXO:0000601
    label: dialysis
  - id: HP:0000100
    label: nephrotic syndrome
  - id: MAXO:0000530
    label: Genetic carrier screening
  - id: MAXO:0000079
    label: Genetic counseling
  - id: HP:0003774
    label: end-stage renal failure
  - id: CHEBI:61049
    label: tacrolimus
  - id: CHEBI:2948
    label: azathioprine
  - id: HP:0100749
    label: Chest pain
  - id: HP:0100607
    label: Dysmenorrhea
  - id: MAXO:0000004
    label: Surgical operations
  - id: MAXO:0000457
    label: Pain management
  - id: HP:0001917
    label: Renal amyloidosis
  - id: MAXO:0000068
    label: Transplantation
  - id: MAXO:0000643
    label: treatment with anti-rheumatic drugs
  - id: HP:0033041
    label: cytokine storm
  - id: CHEBI:35842
    label: anti-rheumatic drugs
  - id: CHEBI:35472
    label: anti-inflammatory drugs
  - id: MONDO:0015137
    label: Periodic fever syndromes
  - id: HP:0011107
    label: aphthous stomatitis
  - id: HP:0025439
    label: pharyngitis
  - id: HP:0002840
    label: adenitis
  - id: HP:0100845
    label: Anaphylaxis
  - id: HP:0002586
    label: Peritonitis
  - id: MONDO:0001343
    label: Kidney disease
